We therefore propose that IL-6’s normally adaptive substrate-mobilizing role becomes maladaptive in cancer: excess FAs that cannot be eniciently oxidized are progressively redirected into membrane lipids and bioactive sphingolipids, predisposing to lipid-driven organelle dysfunction. The gene discussed is IL6; the disease is cancer.